Elite Pharmaceuticals (ELTP) Q3 2025 earnings summary

Executive summary

• Nine-month revenue increased 35% year-over-year to $52M, surpassing last year's full-year total, driven by higher sales of Elite label products, while Q3 revenue was $14.4M, down 8% year-over-year due to shipment delays that rebounded in January.

• Major product launches included generic Vyvanse (Lisdexamfetamine), hydrocodone/APAP, codeine/APAP, methotrexate, and APAP Codeine Tablets, with further FDA approvals and launches expected.

• Net loss for the nine months was $21.3M, compared to net income of $16.8M in the prior year, mainly due to a $27.3M non-cash expense from warrant revaluation.

• Operating income for the nine months was $8.4M, up 19% year-over-year, reflecting improved gross profit despite higher expenses.

• The company is positioned for another record year, with expectations to exceed $70M in annual revenue.

Financial highlights

• Q3 revenue was $14.4M, down from $15.5M in Q3 last year due to shipment timing, and consolidated revenues for Q3 fell 8% year-over-year.

• Nine-month revenue was $52M, up 35% year-over-year, with manufacturing fees up 39% to $50.4M and licensing fees down 34% to $1.6M.

• Gross profit increased 25% to $22.8M, but gross margin declined to 44% from 47% due to higher labor costs and product mix.

• Operating expenses rose 28% to $14.3M, mainly from higher R&D and G&A costs; R&D expense was $1.8M and G&A $2.7M.

• Cash and equivalents at period end were $8.3M, with working capital of $33.4M.

Outlook and guidance

• January 2025 shipments and profits nearly matched the entire Q3, indicating a strong Q4 and management expects to comfortably exceed $70M in revenue for the fiscal year ending March 2025.

• Additional product launches are anticipated, including products acquired from Nostrum and those approved but not yet commercialized.

• The company is expanding manufacturing capacity and expects higher utilization rates to improve margins.

• M&A and Nasdaq uplisting are being actively pursued, with engagement of major financial institutions planned.

• Ongoing litigation and regulatory approvals may impact the timing of certain product launches.